TY - JOUR
T1 - Insulin therapy for treating hypertriglyceridemia - A case report from a tertiary care hospital in coastal Karnataka, India
AU - Chakraborty, Arpita
AU - Stanley, Weena
AU - Mukhyaprana Prabhu, M.
N1 - Publisher Copyright:
© 2020 Malaysian Society for Biochemistry and Molecular Biology. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Severe hypertriglyceridemia (HTG), being one of the most common causes of dyslipidemia is hazardous and predisposing factor leading to increased risk of atherosclerosis and acute pancreatitis. Various genetic disorders leading to disordered metabolism of triglycerides result into primary HTG. We are reporting a case of a 49-year-old non-diabetic male with severe HTG with triglyceride levels of 1032 mg/dl. He was treated with insulin infusion therapy along with fenofibrates and saroglitazar for 3 days as a result of which, TG levels came down to 331 mg/dl. During his follow up visit after 6 months, normal triglyceride level of 105 mg/dl was found. This implies that aggressive treatment and monitoring are required in such patients to ensure an appropriate and optimal therapeutic response and to prevent the development of atherosclerosis and coronary heart disease in future.
AB - Severe hypertriglyceridemia (HTG), being one of the most common causes of dyslipidemia is hazardous and predisposing factor leading to increased risk of atherosclerosis and acute pancreatitis. Various genetic disorders leading to disordered metabolism of triglycerides result into primary HTG. We are reporting a case of a 49-year-old non-diabetic male with severe HTG with triglyceride levels of 1032 mg/dl. He was treated with insulin infusion therapy along with fenofibrates and saroglitazar for 3 days as a result of which, TG levels came down to 331 mg/dl. During his follow up visit after 6 months, normal triglyceride level of 105 mg/dl was found. This implies that aggressive treatment and monitoring are required in such patients to ensure an appropriate and optimal therapeutic response and to prevent the development of atherosclerosis and coronary heart disease in future.
UR - http://www.scopus.com/inward/record.url?scp=85094872611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094872611&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85094872611
SN - 1511-2616
VL - 23
SP - 30
EP - 33
JO - Malaysian Journal of Biochemistry and Molecular Biology
JF - Malaysian Journal of Biochemistry and Molecular Biology
IS - 2
ER -